Secretory phospholipase A2 responsive liposomes

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3146-3159

  Zhu, Guodong ^a   Mock, Jason N ^a   Aljuffali, Ibrahim ^a,c   Cummings, Brian S ^a   Arnold, Robert D ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b AAPS National Meeting   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Controlled release; Drug carriers; Lipids; Liposomes; Mass spectrometry; Metabolism; Nanoparticles

Indexed keywords

1,2 DISTEAROYLGLYCERO 3 PHOSPHATIDIC ACID; 1,2 DISTEAROYLGLYCERO 3 PHOSPHATIDYLETHANOLAMINE; 1,2 DISTEAROYLGLYCERO 3 PHOSPHATIDYLGLYCEROL; 1,2 DISTEAROYLGLYCERO 3 PHOSPHATIDYLSERINE; 1,2 DISTEAROYLGLYCERO 3 PHOSPHOETHANOLAMINE N POLY(ETHYLENEGLYCOL) 2000; 6 CARBOXYFLUORESCEIN; AMPHOLYTE; CHOLESTEROL; DIPALMITOYLPHOSPHATIDYLCHOLINE; DISTEAROYLPHOSPHATIDIC ACID; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; LIPOSOME; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOETHANOLAMINE; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ARTICLE; DRUG RELEASE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; HUMAN; LIPID DEGRADATION; REACTION ANALYSIS;

EID: 79958791034     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22530     Document Type: Article

References (60)

1. Gabizon A. 1989. Liposomes as a drug delivery system in cancer chemotherapy. Horiz Biochem Biophys 9:185-211.
2. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C. 1991. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88(24):11460-11464.
3. Muggia FM. 2001. Liposomal encapsulated anthracyclines: new therapeutic horizons. Current Oncol 3:156-162.
4. Lasic DD, Martin FJ, Gabizon A, Huang SK, Papahadjopoulos D. 1991. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. Biochim Biophys Acta 1070(1):187-192.
5. Sharma US, Sharma A, Chau RI, Straubinger RM. 1997. Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res 14(8):992-998.
6. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65(1-2):271-284.
7. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. 1994. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54(13):3352-3356.
8. Straubinger RM, Arnold RD, Zhou R, Mazurchuk R, Slack JE. 2004. Antivascular and antitumor activities of liposome-associated drugs. Anticancer Res 24(2A):397-404.
9. Bondurant B, Mueller A, O'Brien DF. 2001. Photoinitiated destabilization of sterically stabilized liposomes. Biochim Biophys Acta 1511(1):113-122.
10. Shum P, Kim JM, Thompson DH. 2001. Phototriggering of liposomal drug delivery systems. Adv Drug Deliv Rev 53(3):273-284.
11. Spratt T, Bondurant B, O'Brien DF. 2003. Rapid release of liposomal contents upon photoinitiated destabilization with UV exposure. Biochim Biophys Acta 1611(1-2):35-43.
12. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. 1978. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202(4374):1290-1293.
13. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. 2000. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 60(24):6950-6957.
14. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. 2000. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60(5):1197-1201.
15. Huang SL, MacDonald RC. 2004. Acoustically active liposomes for drug encapsulation and ultrasound-triggered release. Biochim Biophys Acta 1665(1-2):134-141.
16. Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, Talmon Y, Kost J, Barenholz Y. 2007. Controlling liposomal drug release with low frequency ultrasound: mechanism and feasibility. Langmuir 23(7):4019-4025.
17. Hafez IM, Cullis PR. 2001. Roles of lipid polymorphism in intracellular delivery. Adv Drug Deliv Rev 47(2-3):139-148.
18. Goni FM, Alonso A. 2000. Membrane fusion induced by phospholipase C and sphingomyelinases. Biosci Rep 20(6):443-463.
19. Ruiz-Arguello MB, Goni FM, Alonso A. 1998. Vesicle membrane fusion induced by the concerted activities of sphingomyelinase and phospholipase C. J Biol Chem 273(36):22977-22982.
20. Wilschut JC, Regts J, Westenberg H, Scherphof G. 1978. Action of phospholipases A2 on phosphatidylcholine bilayers. Effects of the phase transition, bilayer curvature and structural defects. Biochim Biophys Acta 508(2):185-196.
21. Andresen TL, Davidsen J, Begtrup M, Mouritsen OG, Jorgensen K. 2004. Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J Med Chem 47(7):1694-1703.
22. Andresen TL, Jensen SS, Kaasgaard T, Jorgensen K. 2005. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr Drug Deliv 2(4):353-362.
23. Jensen SS, Andresen TL, Davidsen J, Hoyrup P, Shnyder SD, Bibby MC, Gill JH, Jorgensen K. 2004. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther 3(11):1451-1458.
24. Dong Q, Patel M, Scott KF, Graham GG, Russell PJ, Sved P. 2006. Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett 240(1):9-16.
25. Kallajoki M, Alanen KA, Nevalainen M, Nevalainen TJ. 1998. Group II phospholipase A2 in human male reproductive organs and genital tumors. Prostate 35(4):263-272.
26. Jiang J, Neubauer BL, Graff JR, Chedid M, Thomas JE, Roehm NW, Zhang S, Eckert GJ, Koch MO, Eble JN, Cheng L. 2002. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 160(2):667-671.
27. Graff JR, Konicek BW, Deddens JA, Chedid M, Hurst BM, Colligan B, Neubauer BL, Carter HW, Carter JH. 2001. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 7(12):3857-3861.
28. Yamashita S, Yamashita J, Ogawa M. 1994. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69(6):1166-1170.
29. Yamashita S, Ogawa M, Sakamoto K, Abe T, Arakawa H, Yamashita J. 1994. Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta 228(2):91-99.
30. Yamashita S, Yamashita J, Sakamoto K, Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K, Ogawa M. 1993. Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer 71(10):3058-3064.
31. Kiyohara H, Egami H, Kako H, Shibata Y, Murata K, Ohshima S, Sei K, Suko S, Kurano R, Ogawa M. 1993. Immunohistochemical localization of group II phospholipase A2 in human pancreatic carcinomas. Int J Pancreatol 13(1):49-57.
32. Kuopio T, Ekfors TO, Nikkanen V, Nevalainen TJ. 1995. Acinar cell carcinoma of the pancreas. Report of three cases. APMIS 103(1):69-78.
33. Oka Y, Ogawa M, Matsuda Y, Murata A, Nishijima J, Miyauchi K, Uda K, Yasuda T, Mori T. 1990. Serum immunoreactive pancreatic phospholipase A2 in patients with various malignant tumors. Enzyme 43(2):80-88.
34. Sved P, Scott KF, McLeod D, King NJ, Singh J, Tsatralis T, Nikolov B, Boulas J, Nallan L, Gelb MH, Sajinovic M, Graham GG, Russell PJ, Dong Q. 2004. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res 64(19):6934-6940.
35. Cummings BS, McHowat J, Schnellmann RG. 2000. Phospholipase A(2)s in cell injury and death. J Pharmacol Exp Ther 294(3):793-799.
36. Wilschut JC, Regts J, Scherphof G. 1979. Action of phospholipase A2 on phospholipid vesicles. Preservation of the membrane permeability barrier during asymmetric bilayer degradation. FEBS Lett 98(1):181-186.
37. Menashe M, Romero G, Biltonen RL, Lichtenberg D. 1986. Hydrolysis of dipalmitoylphosphatidylcholine small unilamellar vesicles by porcine pancreatic phospholipase A2. J Biol Chem 261(12):5328-5333.
38. Bartlett GR. 1959. Phosphorus assay in column chromatography. J Biol Chem 234(3):466-468.
39. Bligh EG, Dyer WJ. 1959. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37(8):911-917.
40. Sato H, Kato R, Isogai Y, Saka G-i, Ohtsuki M, Taketomi Y, Yamamoto K, Tsutsumi K, Yamada J, Masuda S, Ishikawa Y, Ishii T, Kobayashi T, Ikeda K, Taguchi R, Hatakeyama S, Hara S, Kudo I, Itabe H, Murakami M. 2008. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem 283(48):33483-33497.
41. Faas FH, Dang AQ, Pollard M, Hong XM, Fan K, Luckert PH, Schutz M. 1996. Increased phospholipid fatty acid remodeling in human and rat prostatic adenocarcinoma tissues. J Urol 156(1):243-248.
42. Nevalainen TJ, Eskola JU, Aho AJ, Havia VT, Lovgren TN, Nanto V. 1985. Immunoreactive phospholipase A2 in serum in acute pancreatitis and pancreatic cancer. Clin Chem 31(7):1116-1120.
43. Birts CN, Barton CH, Wilton DC. 2008. A catalytically independent physiological function for human acute phase protein group IIA phospholipase A2: cellular uptake facilitates cell debris removal. J Biol Chem 283(8):5034-5045.
44. Groeneveld AB, Tacx AN, Bossink AW, van Mierlo GJ, Hack CE. 2003. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol 106(2):106-115.
45. Leidy C, Linderoth L, Andresen TL, Mouritsen OG, Jorgensen K, Peters GH. 2006. Domain-induced activation of human phospholipase A2 type IIA: local versus global lipid composition. Biophys J 90(9):3165-3175.
46. Buckland AG, Wilton DC. 2000. Anionic phospholipids, interfacial binding and the regulation of cell functions. Biochim Biophys Acta 1483(2):199-216.
47. Bajoria R, Sooranna SR, Contractor SF. 1997. Endocytotic uptake of small unilamellar liposomes by human trophoblast cells in culture. Hum Reprod 12(6):1343-1348.
48. Kokkona M, Kallinteri P, Fatouros D, Antimisiaris SG. 2000. Stability of SUV liposomes in the presence of cholate salts and pancreatic lipases: effect of lipid composition. Eur J Pharm Sci 9(3):245-252.
49. Weinstein JN, Yoshikami S, Henkart P, Blumenthal R, Hagins WA. 1977. Liposome-cell interaction: transfer and intracellular release of a trapped fluorescent marker. Science 195(4277):489-492.
50. Gabizon A, Shiota R, Papahadjopoulos D. 1989. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J Natl Cancer Inst 81(19):1484-1488.
51. Arnold RD, Mager DE, Slack JE, Straubinger RM. 2005. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model. Clin Cancer Res 11(24 Pt 1):8856-8865.
52. Putz T, Ramoner R, Gander H, Rahm A, Bartsch G, Thurnher M. 2006. Antitumor action and immune activation through cooperation of bee venom secretory phospholipase A2 and phosphatidylinositol-(3, 4)-bisphosphate. Cancer Immunol Immunother 55(11):1374-1383.
53. Andresen TL, Jensen SS, Jorgensen K. 2005. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44(1):68-97.
54. Davidsen J, Jorgensen K, Andresen TL, Mouritsen OG. 2003. Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim Biophys Acta 1609(1):95-101.
55. Davidsen J, Mouritsen OG, Jorgensen K. 2002. Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes. Biochim Biophys Acta 1564(1):256-262.
56. Davidson FF, Dennis EA. 1990. Amino acid sequence and circular dichroism of Indian cobra (Naja naja naja) venom acidic phospholipase A2. Biochim Biophys Acta 1037(1):7-15.
57. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51(4):691-743.
58. Gabizon A, Papahadjopoulos D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 85(18):6949-6953.
59. Papahadjopoulos D, Gabizon A. 1990. Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res 343:85-93.
60. Peterson BL, Cummings BS. 2006. A review of chromatographic methods for the assessment of phospholipids in biological samples. Biomed Chromatogr 20(3):227-243.